

ASX RELEASE | OSTEOPORE LIMITED

CFO Resignation

18 January 2022: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants at commercial scale empowering natural tissue regeneration, would like to inform shareholders of the resignation of Chief Financial Officer (“CFO”), Carl Runde, allowing Mr Runde to pursue other opportunities.

Commenting on Mr Runde’s departure, Khoon Seng Goh, Osteopore’s CEO said: “I wish to thank Carl for being part of Team Osteopore, and for his assistance in growing out the finance team ASX experience and capabilities.”

The Company’s finance operational support team based in Singapore will work with the OSX external accounts team who have been providing the Company with accounting services since the IPO in September 2019. The Board will continue to ensure continuous disclosure, external reporting obligations and best-practice financial disciplines are met as a publicly listed company.

Mr Runde will continue as Osteopore’s CFO until the completion of Osteopore’s 2021 full year financial results. The Company will actively recruit a new CFO to join the leadership team and is expecting to make that appointment as soon as the appropriate candidate is identified.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.